Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Haematologica|November 16, 2016
Effect of high-dose plerixafor on CD34<sup>+</sup> cell mobilization in healthy stem cell donors: results of a randomized crossover trialJeremy Pantin, Enkhtsetseg Purev, Xin Tian, et al.
Blood|April 23, 2008
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interactionSteven M Devine, Ravi Vij, Michael Rettig, et al.
Cytotherapy|November 26, 2009
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II studyStefan Fruehauf, Marlon Romano Veldwijk, Timon Seeger, et al.
Supportive Cancer Therapy|July 17, 2008
Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 AntagonistKai Hübel, W Conrad Liles, Hal E Broxmeyer, et al.
Experimental Hematology|July 26, 2006
The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristicsStefan Fruehauf, Timon Seeger, Patrick Maier, et al.
British Journal of Haematology|March 1, 2011
A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteersSteven J Lemery, Matthew M Hsieh, Aleah Smith, et al.
Blood|April 14, 2009
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaJohn F DiPersio, Edward A Stadtmauer, Auayporn Nademanee, et al.
The Journal of Experimental Medicine|April 20, 2005
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonistHal E Broxmeyer, Christie M Orschell, D Wade Clapp, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix, Ann C Collier, Michael M Lederman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 19, 2013
Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSFAndreas Lundqvist, Aleah L Smith, Yoshiyuki Takahashi, et al.
Pageof 3